Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (71-80 of 824) with videos related to

Pageof 83
Sort By:
JAMA Oncology|May 15, 2025
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?Sean M McBride, Howard I Scher
Urologic Oncology|January 27, 2015
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approvalGabriel P Haas, Howard I Scher
Urologic Oncology|March 24, 2015
Enzalutamide: Development from bench to bedsideR M Bambury, H I Scher
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Cancer|December 1, 1992
Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicityJ A Conti, H I Scher
European Urology|September 5, 2016
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on DefinitionsEmmanuel S Antonarakis, Howard I Scher
Seminars in Urologic Oncology|August 26, 1999
Rising PSAs after primary therapy: active or passive interventionS F Slovin, H I Scher
Seminars in Oncology|December 1, 1991
The evolving role of chemotherapy for muscle infiltrating bladder cancerA D Seidman, H I Scher
Expert Review of Anticancer Therapy|August 14, 2018
Apalutamide for the treatment of prostate cancerDana E Rathkopf, Howard I Scher
Pageof 83

Showing results (71-80 of 824) with videos related to

Sort By:
Pageof 83
JAMA Oncology|May 15, 2025
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?Sean M McBride, Howard I Scher
Urologic Oncology|January 27, 2015
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approvalGabriel P Haas, Howard I Scher
Urologic Oncology|March 24, 2015
Enzalutamide: Development from bench to bedsideR M Bambury, H I Scher
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?Matthew D Galsky, Howard I Scher
Cancer|December 1, 1992
Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicityJ A Conti, H I Scher
European Urology|September 5, 2016
Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on DefinitionsEmmanuel S Antonarakis, Howard I Scher
Seminars in Urologic Oncology|August 26, 1999
Rising PSAs after primary therapy: active or passive interventionS F Slovin, H I Scher
Seminars in Oncology|December 1, 1991
The evolving role of chemotherapy for muscle infiltrating bladder cancerA D Seidman, H I Scher
Expert Review of Anticancer Therapy|August 14, 2018
Apalutamide for the treatment of prostate cancerDana E Rathkopf, Howard I Scher
Pageof 83